Abigail E. Gregor

Partner

hackler-abigail-e
  • JD, cum laude, Harvard Law School, 2011; Journal of Sports & Entertainment Law , Managing Editor and Technical Editor
  • BS (Industrial & Labor Relations), with Honors, Cornell University, 2006

Qualifications

  • Massachusetts, 2011
  • LMG Life Sciences Americas Awards “M&A Firm of the Year” (2022)

Abigail E. Gregor

Partner

Abigail (Abby) Gregor advises clients across the life sciences and biotech sectors in a wide range of strategic transactions, including license agreements, complex collaborations, product funding and co-development agreements, royalty monetization transactions and general commercial agreements. She represents pharmaceutical, biotech and medical device companies, academic and institutional clients, and life sciences-focused investment funds.

Abby’s breadth of experience, including her secondment as an associate general counsel at a global pharmaceutical company, enables her to bring a pragmatic, business-oriented perspective to her work. Clients look to Abby for her collaborative approach when negotiating transactions— an approach that fosters the formation of longstanding partnerships between clients and counterparties while minimizing the traditional adversarial nature of negotiations. 

A passionate advocate for causes related to women and children, Abby is also actively involved with several pro bono organizations focused on education, immigration, and the empowering of women, such as Rosie’s Place, the Medical-Legal Partnership | Boston and My Life My Choice.

Experience

Licensing and Collaboration Matters

  • IDRx in licensing transactions with Germany-based Merck KGaA and Blueprint Medicines to secure rights to precision therapies to treat cancer in connection with $122 million Series A financing. 
  • Sanofi in an exclusive worldwide collaboration with Skyhawk Therapeutics for up to more than $2 billion to discover and develop novel small molecules that modulate RNA splicing for challenging oncology and immunology disease targets with limited or no therapeutic options.
  • EQRx in multiple discovery collaborations and license agreements to further EQRx’s mission of developing and delivering innovative medicines to patients at lower prices, including with Exscientia, AbCellera, Relay Therapeutics, Absci, Aurigene, Turning Point Therapeutics, Evotec, Abdul Latif Jameel Health and Insilico Medicine.
  • Immunogen in a global, multi-target license with Eli Lilly and Company for up to $1.7B to research, develop and commercialize ADCs to targets selected by Lilly based on ImmunoGen’s novel camptothecin drug technology.
  • Ovid Therapeutics in a strategic partnership with U.K.-based Healx, granting Healx the exclusive option to license rights to develop and commercialize gaboxadol.
  • Johnson & Johnson in connection with various licensing and collaboration agreements.
  • Ironwood Pharmaceuticals in a collaboration and license option agreement with COUR Pharmaceutical Development Company to develop and commercialize COUR’s investigational therapy (CNP-104) to treat PBC, a rare autoimmune disease.
  • G1 Therapeutics in multiple license and collaboration agreements, including:
    • An exclusive license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib in the Asia-Pacific region (excluding Japan).
    • An exclusive license agreement with EQRx, Inc. for the development and commercialization of lerociclib worldwide, excluding the Asia-Pacific region (except Japan).
    • An exclusive license agreement with Simcere for the development and commercialization of trilaciclib across all indications in Greater China (mainland China, Hong Kong, Macau and Taiwan).
  • Vertex Pharmaceuticals in its collaboration with Affinia Therapeutics to develop genetic therapies for Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and cystic fibrosis through the use of Affinia’s AAV capsid engineering platform.
  • BlueRock Therapeutics in its collaboration and cross-license with Editas Medicine combining BlueRock’s engineered cell therapy technology with Editas’ genome editing technology to create new pluripotent stem cell lines, and to create cell medicines in the oncology field.
  • Alexion Pharmaceuticals in its collaboration with Dicerna Pharmaceuticals to develop RNAi therapies for complement mediated diseases using Dicerna’s GAlXC platform.
  • Verastem Oncology in its regional exclusive out-licensing of Duvelisib to CSPC Pharmaceutical Group Limited (Greater China), Yakult Honsha Co. (Japan) and Sanofi (Africa, Middle East and Eurasia).
  • Astellas Pharma in its license and collaboration agreement with Xencor, Inc. to generate bispecific antibody candidates against certain oncology targets, with Astellas having worldwide rights to develop and commercialize novel drug candidates resulting therefrom.
  • Brii Biosciences in its collaboration with (and equity investment in) Artizan Biosciences to develop and commercialize novel anti-inflammatory therapeutic products in greater China using Artizan’s proprietary IgA-SEQ technology platform.
  • Brii Biosciences in its collaboration with Qpex Biopharma to develop and commercialize novel antibiotics in greater China.
  • Strata Oncology in its collaboration with Arcus Biosciences for Arcus’ anti-PD-1 antibody utilizing Strata’s precision drug development platform.
  • The Broad Institute in its worldwide exclusive licensing agreement with Beam Therapeutics Inc. for certain gene editing intellectual property rights. 
  • Zai Lab Limited with an exclusive license agreement with Five Prime Therapeutics for FPA144 Anti-FGFR2b antibody in Greater China.
  • Zai Lab Limited with a collaboration and license agreement with Entasis Therapeutics Holdings to develop and commercialize Entasis’s proprietary compounds in mainland China and several other Asian countries, as well as Australia and New Zealand.
  • Alexion Pharmaceuticals in its collaboration and licensing agreement with Halozyme Therapeutics to use Halozyme’s ENHANZE drug delivery technology in the development of Alexion’s rare disease drug product portfolio.
  • CANbridge Life Sciences in its $144 million collaboration and license agreement with AVEO Oncology for worldwide rights to AV-203, AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate, with exclusions.
  • A large global pharmaceutical company in its global strategic collaboration with a clinical-stage biopharmaceutical company to develop and commercialize a PI3K inhibitor for the treatment of patients with cancer.
  • Alexion Pharmaceuticals with its strategic license agreement with Moderna Therapeutics for $100 million to purchase 10 product options to develop and commercialize treatments for rare diseases utilizing Moderna’s mRNA Therapeutics platform.

Mergers and Acquisitions

  • Cullinan Oncology in a strategic collaboration with Taiho Pharmaceutical under which Taiho acquired Cullinan Oncology’s subsidiary Cullinan Pearl for $275 million, with the potential to receive up to an additional $130 million in regulatory-based milestone payments. 
  • Life sciences counsel to Blackstone Life Sciences in its acquisition of Clarus, a leading global life sciences investment firm that recently closed its inaugural fund with $4.6 billion in capital commitments.
  • Verastem Oncology in its sale of COPIKTRA® (duvelisib) to Secura Bio, for $70 million up-front, with a total deal value of $311 million, plus double-digit royalties on net sales over $100 million in the U.S., Europe and the UK.
  • Groupe Rocher with its acquisition of Arbonne International, a leader in direct selling of botanically based beauty, personal care and nutrition products.
  • Pfizer in its transaction with Allogene Therapeutics for Pfizer's portfolio of assets related to allogeneic chimeric antigen receptor T cell (CAR T) therapy, an investigational immune cell therapy approach to treating cancer.
  • Pfizer in its $130 million acquisition of two meningitis vaccines from GlaxoSmithKline.

Life Sciences Private Equity Transactions

  • Blackstone Life Sciences in its combination with gene editing drugmaker Intellia Therapeutics, Inc. and German cell manufacturer Cellex Cell Professionals GmbH to create a new CAR T-cell company to develop cell therapies for cancer and autoimmune diseases.  
  • Blackstone Life Sciences in its $2 billion, IP-intensive and strategic collaboration to support Alnylam’s advancement of innovative RNA interference (RNAi) medicines, including:
    • The purchase of 50% of Alnylam’s royalties and commercial milestones for inclisiran in exchange for $1 billion in committed payments; and
    • A Product Funding Agreement with up to $150 million paid by Blackstone Life Sciences for the development of Alnylam’s cardiometabolic programs vutrisiran and ALN-AGT.
  • Bain Capital in its $125 Million non-dilutive financing with Cerevel Therapeutics to fund the Phase 3 development program for tavapadon in Parkinson’s disease, also known as the TEMPO trials.

Commercial Agreements

  • Serves as outside counsel to a variety of companies, providing ongoing support for complex commercial agreements including Clinical and Commercial Supply Agreements, Manufacturing Agreements, Sponsored Research Agreements, Clinical Trial Agreements, Master Services Agreements, Material Transfer Agreements, etc.

    Representative clients include:
    • ImmunoGen
    • TransMedics
    • Thermo Fisher Scientific

Publications

Presentations

  • Presenter, “Clinical Trial Data Sharing and Machine Learning Research,” Vivli Center for Global Clinical Research Data Webinar (March 2021)
  • JD, cum laude, Harvard Law School, 2011; Journal of Sports & Entertainment Law , Managing Editor and Technical Editor
  • BS (Industrial & Labor Relations), with Honors, Cornell University, 2006

Qualifications

  • Massachusetts, 2011
  • LMG Life Sciences Americas Awards “M&A Firm of the Year” (2022)
Cookie Settings